Edition:
United States

SAGE Therapeutics Inc (SAGE.O)

SAGE.O on Consolidated Issue listed on NASDAQ Global Market

174.26USD
14 Jun 2019
Change (% chg)

$-1.58 (-0.90%)
Prev Close
$175.84
Open
$175.15
Day's High
$177.52
Day's Low
$173.60
Volume
203,554
Avg. Vol
493,462
52-wk High
$178.16
52-wk Low
$79.88

About

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and... (more)

Overall

Beta: 2.58
Market Cap(Mil.): $8,913.00
Shares Outstanding(Mil.): 51.15
Dividend: --
Yield (%): --

Financials

  SAGE.O Industry Sector
P/E (TTM): -- 103.12 37.45
EPS (TTM): -9.74 -- --
ROI: -38.20 7.69 12.16
ROE: -38.82 8.19 16.93

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

Mar 21 2019

UPDATE 5-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

CHICAGO/TOKYO, March 21 Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

Mar 21 2019

Sage gets U.S. approval for first postpartum depression therapy

The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby. | Video

Mar 20 2019

UPDATE 3-Sage gets U.S. approval for first postpartum depression therapy

March 19 The U.S. Food and Drug Administration on Tuesday approved https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.

Mar 19 2019

CORRECTED-Sage gets U.S. approval for first postpartum depression therapy

March 19 The U.S. Food and Drug Administration on Tuesday approved https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.

Mar 19 2019

Sage shares soar after oral postpartum depression treatment succeeds in trial

Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

Jan 07 2019

UPDATE 1-Sage shares soar after oral postpartum depression treatment succeeds in trial

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study, sending its shares up 33 percent.

Jan 07 2019

Sage's oral postpartum depression treatment succeeds in late-stage study

Jan 7 Sage Therapeutics Inc said on Monday its oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared to a placebo in a late-stage study.

Jan 07 2019

Earnings vs. Estimates